Drugs / JP-1730
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00040209 | Jun 2002 → Jul 2005 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JP-1730 | “This study will evaluate the effects of an experimental drug called JP-1730 on Parkinson's disease symptoms” NCT00040209 ↗ |
| Action | Inhibit | “selective alpha-2 adrenergic receptor antagonism” NCT00040209 ↗ |
| Route | Oral | “via puffs from an oral spray” NCT00040209 ↗ |